Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or New Jersey for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to New Jersey only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. New Jersey (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Richard Haddad (NPI 1750382800)

Field	Value
Entity Type	Individual
Organization	Richard Haddad
Address	282 Broad St
City	Red Bank
State	NJ
ZIP	07701
Taxonomy	Specialist
NPI Enumerated	August 10, 2005

Payer Source	Total Paid
Medicare	$4.3M
Medicaid	$0

Key Findings

This provider is effectively a Medicare-only biller: total Medicare revenue is $4.3M while there is no Medicaid billing on file. That payer mix makes the practice highly dependent on Medicare reimbursement and exposes its topline to shifts in Medicare drug administration and infusion policy.

Revenue is highly concentrated in a small set of biologic infusion codes: the top three Medicare codes (J0717, J0129, J3262) account for 65.5% of this provider's Medicare revenue. Individually those codes generate $1.3M (J0717, 29.1%), $1.1M (J0129, 24.4%), and $520.2K (J3262, 12.1%), indicating most revenue derives from high-volume injectable biologic therapies.

The procedure and drug mix points to an infusion- and injection-oriented specialist practice: large volumes for J0717 (certolizumab), J0129 (abatacept), J3262 (tocilizumab) and other biologic J‑codes, combined with notable billing for infusion/administration CPTs such as 96413 and 96401, suggest on-site supervised drug administration and episodic infusion visits rather than a primarily office-visit driven model. Office E/M codes (for example, 99213 with $54.9K revenue and 99214 with $33.2K revenue) appear but are secondary to drug/infusion revenue.

Several codes show the provider is a national high-volume outlier for specific therapies: J0717 ranks #5 of 848 providers nationally (100th percentile; extreme outlier, far above typical national volume for this code) and J0129 ranks #40 of 1221 (97th percentile; notably above typical national volume). High ranks for chemotherapy/infusion administration—96413 ranks #58 of 7514 (99th percentile; extreme outlier) and 96401 ranks #18 of 3868 (100th percentile; extreme outlier)—reinforce that this provider operates at well-above-typical scale for certain infusion services.

Not all lines are outliers: J3262 ($520.2K, 12.1% of revenue) ranks #49 of 618 (92th percentile; typical, unremarkable volume for this code) and many E/M and smaller procedural codes (for example, 20611 at $14.1K, rank in the 79th percentile) sit at or near typical national volumes. This mix of extreme outlier drugs plus otherwise typical service lines suggests concentrated dominance in a few drugs rather than uniformly high volumes across the full service portfolio.

The provider demonstrates very high procedural throughput for certain administration codes that support an infusion-focused business model: 96372 shows 1.1K claims and $12.6K revenue while ranking #347 of 58224 providers nationally (99th percentile; extreme outlier, far above typical national volume for this code). Similarly, J0702 appears with 1.9K claims and $9.6K revenue and ranks in the 99th percentile, indicating frequent brief injection encounters in addition to larger infusion episodes.

Concentration risk is material given the dependence on a few high-revenue biologic codes; policy, reimbursement, or formulary changes affecting J0717 or J0129 could meaningfully impact the $4.3M Medicare revenue base. With 65.5% of Medicare revenue tied to the top three codes, payers and partners should treat utilization shifts for those specific drugs as high-impact for this provider.

The provider has established tenure in Medicare billing, with NPI enumeration dated 2005-08-10 (~21 years ago), indicating longstanding participation in Medicare. That length of enrollment, combined with very high national ranks on select infusion codes, positions the provider as a specialized, high-volume Medicare infusion administrator rather than a general outpatient practice.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

33 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J0717	Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	313,200	$1	$1.3M
J0129	Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	31,880	$30	$1.1M
J3262	Injection, tocilizumab, 1 mg	104,040	$10	$520.2K
J1602	Injection, golimumab, 1 mg, for intravenous use	45,100	$10	$451K
J0490	Injection, belimumab, 10 mg	7,850	$40	$313.9K
J3111	Injection, romosozumab-aqqg, 1 mg	18,480	$10	$147.8K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	1,080	$110	$122.7K
J0897	Injection, denosumab, 1 mg	5,760	$20	$103.7K
96401	The provider administers nonhormonal, antineoplastic chemotherapy drugs subcutaneously or intramuscularly to the patient.	1,570	$60	$100.7K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	810	$70	$54.9K

Showing 1–10 of 33

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 33 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. New Jersey Distribution

Richard Haddad — 8 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — New Jersey

Full comparison — all codes billed, vs. state median

33 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J0129	1	40	7,600	$30	$297K
J0490	1	10	7,360	$40	$293K
J3262	2	20	33,800	$1	$227.5K
J0717	1	60	42,300	$1	$219.5K
J1602	4	40	12,580	$10	$165.7K
J3111	5	30	12,600	$10	$107.3K
J0897	100	380	3,060	$20	$87.8K
J7329	15	70	2,680	$10	$35.7K
J3304	26	40	1,400	$10	$32.8K
96413	1	230	190	$110	$26.6K

Showing 1–10 of 33

Related Providers

Other providers that share a Tax Identification Number (TIN) with Richard Haddad, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Edward Allegra	NJ	Specialist	$3.6M	$0
Mia Collucci	NJ	Medical Physician Assistant	$446.8K	$0

Nearby Providers

Other providers in the same ZIP code as Richard Haddad, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Cpc Integrated Health, Inc.	NJ	Community/Behavioral Health Agency	$0	$80.7M
Hackensack Meridian Health Medical Group - Specialty Care PC	NJ	Surgical Critical Care Physician	$0	$50.1M
Hmh Hospitals Corporation	NJ	General Acute Care Hospital	$0	$26.4M
Caring With Compassion	NJ	Developmentally Disabled Services Day Training Agency	$0	$23.7M
Hackensack Meridian Health Medical Group - Primary Care PC	NJ	Family Medicine Physician	$0	$21.9M
Cpc Integrated Health, Inc.	NJ	Mental Health Clinic/Center (Including Community Mental Health Center)	$0	$16M
Hackensack Meridian Health Medical Group - Complex Care PC	NJ	Internal Medicine Physician	$0	$11.6M
Cpc Integrated Health, Inc.	NJ	Mental Health Clinic/Center (Including Community Mental Health Center)	$0	$8.8M
Meridian Medical Group - Specialty Care, PC	NJ	Specialist	$0	$8.2M
Middletown Medical, LLC	NJ	Methadone Clinic	$454.8K	$7.8M

Richard Haddad — Billing Profile & Reimbursement Data

Sign up for Richard Haddad — Billing Profile & Reimbursement Data policy alerts

Richard Haddad — Billing Profile & Reimbursement Data

Sign up for Richard Haddad — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References